An ethics framework for consolidating and prioritizing COVID-19 clinical trials.
- Published in:
- Clinical Trials, 2021, v. 18, n. 2, p. 226, doi. 10.1177/1740774520988669
- By:
- Publication type:
- Article
Works matching IS 17407745 AND DT 2021 AND VI 18 AND IP 2
Results: 15
1
2
Commentary on Meyers et al: Ethically prioritizing trials in the COVID-19 era – practical considerations.
- Published in:
- Clinical Trials, 2021, v. 18, n. 2, p. 234, doi. 10.1177/1740774520988663
- By:
- Publication type:
- Article
3
Research Attitudes Questionnaire scores predict Alzheimer's disease clinical trial dropout.
- Published in:
- Clinical Trials, 2021, v. 18, n. 2, p. 237, doi. 10.1177/1740774520982315
- By:
- Publication type:
- Article
4
Importance of incorporating quantitative imaging biomarker technical performance characteristics when estimating treatment effects.
- Published in:
- Clinical Trials, 2021, v. 18, n. 2, p. 197, doi. 10.1177/1740774520981934
- By:
- Publication type:
- Article
5
A case study of ascertainment bias for the primary outcome in the Strategies to Reduce Injuries and Develop Confidence in Elders (STRIDE) trial.
- Published in:
- Clinical Trials, 2021, v. 18, n. 2, p. 207, doi. 10.1177/1740774520980070
- By:
- Publication type:
- Article
6
Are restricted mean survival time methods especially useful for noninferiority trials?
- Published in:
- Clinical Trials, 2021, v. 18, n. 2, p. 188, doi. 10.1177/1740774520976576
- By:
- Publication type:
- Article
7
Optimal design of cluster randomised trials with continuous recruitment and prospective baseline period.
- Published in:
- Clinical Trials, 2021, v. 18, n. 2, p. 147, doi. 10.1177/1740774520976564
- By:
- Publication type:
- Article
8
Dynamic methods for ongoing assessment of site-level risk in risk-based monitoring of clinical trials: A scoping review.
- Published in:
- Clinical Trials, 2021, v. 18, n. 2, p. 245, doi. 10.1177/1740774520976561
- By:
- Publication type:
- Article
9
Experience of conducting clinical trials of investigational medicinal products during a respiratory virus pandemic: Lessons learnt from COVID-19.
- Published in:
- 2021
- By:
- Publication type:
- Letter
10
Data management in substance use disorder treatment research: Implications from data harmonization of National Institute on Drug Abuse-funded randomized controlled trials.
- Published in:
- Clinical Trials, 2021, v. 18, n. 2, p. 215, doi. 10.1177/1740774520972687
- By:
- Publication type:
- Article
11
Event-specific win ratios and testing with terminal and non-terminal events.
- Published in:
- Clinical Trials, 2021, v. 18, n. 2, p. 180, doi. 10.1177/1740774520972408
- By:
- Publication type:
- Article
12
Online monitoring of patient self-reported adverse events in early phase clinical trials: Views from patients, clinicians, and trial staff.
- Published in:
- Clinical Trials, 2021, v. 18, n. 2, p. 168, doi. 10.1177/1740774520972125
- By:
- Publication type:
- Article
13
Lack of harmonization of coronavirus disease ordinal scales.
- Published in:
- 2021
- By:
- Publication type:
- Letter
14
Clinical trial monitoring effectiveness: Remote risk-based monitoring versus on-site monitoring with 100% source data verification.
- Published in:
- Clinical Trials, 2021, v. 18, n. 2, p. 158, doi. 10.1177/1740774520971254
- By:
- Publication type:
- Article
15
Bayesian biomarker-driven outcome-adaptive randomization with an imperfect biomarker assay.
- Published in:
- Clinical Trials, 2021, v. 18, n. 2, p. 137, doi. 10.1177/1740774520964202
- By:
- Publication type:
- Article